Enable precision immuno-oncology with high-resolution adaptive immune repertoire profiling
From checkpoint blockade to engineered cell therapy, a deep understanding of the adaptive immune response is essential for generating actionable insights in immuno-oncology. Yet most profiling approaches provide only partial, tumor-centric views, missing the clonal dynamics and immune remodeling events that influence clinical outcomes.
iRepertoire delivers quantitative, adaptive immune receptor repertoire profiling at both bulk and single-cell resolutions with low bias and high sensitivity. With advanced data analysis and expert scientific support, we help translational teams identify antigen-specific receptor sequences, evaluate and QC engineered CAR-T and TIL products, track clonal expansion and persistence, detect early resistance signals, and uncover clinically meaningful biomarkers that guide patient selection and therapeutic development.
Uncover immune signatures that predict and shape cell therapy response
Tracking T cell repertoire dynamics in response to cell therapy
Predicting how patients will respond to T-cell-based therapies is a growing priority for researchers working to personalize treatment and improve clinical outcomes. High-resolution TCR profiling enables teams to monitor clonal behavior, identify which clones drive the response, and link immune activity to therapeutic performance.
Explore this case study to see how iRepertoire’s single-cell TCR sequencing enabled:
- Correlation of TCR repertoire diversity with patient prognosis, revealing why individuals with higher baseline diversity experience more favorable immunotherapy outcomes.
- Identification and tracking of neoantigen-specific T cell clones, demonstrating how clonal expansion after personalized vaccine treatment reflects immune activation.
- Characterization of antigen-specific CD8+ T cells responding to novel therapeutic modalities, including selective expansion and immunologic memory.
See how our platform transforms immune data into infectious disease insights
Immune repertoire profiling reveals patient responses to immunotherapy, such as immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) prevent cancer cells from escaping detection by the host immune system, however only 20-40% of patients respond.
Because these compounds act on many different types of immune cells, emerging studies indicate that understanding a patient’s immune repertoire is critical to mapping ICI therapy response. In one case study, examination of pre- and post-treatment samples from patients treated with ICIs identified a novel signature involving immune checkpoint proteins that was associated with a positive clinical result.
PUBLICATION
Clinical outcomes following immune checkpoint inhibitor treatment
PUBLICATION
Risk factors that contribute to inhibitor therapy response
POSTER
Evaluating renal cancer treatment
WEBINAR
Predicting treatment response in renal cancer
CASE STUDY
Pre- and post-treatment monitoring in cancer
Immune profiling to track tumor infiltrating lymphocytes in patient blood
Comprehensive and quantitative immune repertoire sequencing data allows clinical researchers to identify which T cells are in the tumor, monitor the T cell populations in the TIL therapy production pipeline, and track the T cells over time in an individual patient.
A poster presentation demonstrates how immune profiling was used to monitor tumor infiltrating lymphocytes in advanced metastatic melanoma patients treated with TIL therapy.
POSTER
Bulk TIL products can treat solid tumors in a patient-specific manner
POSTER
Using iPair/iPair+ to track TILs
POSTER
PD1-positive TIL for adoptive T cell therapy
Repertoire analysis of ex vivo antigen-stimulated T cells derived from PBMC can reveal expanded clonotypes
T-cells derived from autologous peripheral blood can be stimulated with peptide-loaded dendritic cells or other methods. Immune repertoire sequencing or single cell sequencing can reveal the identity of expanded TCRs and characterize the T-cell product in a similar manner to TIL or Car-T therapies. These clonotypes can then be tracked in patients to observe and track the expansion or contraction of the clones in vivo. By uncovering the peptide-antigenic synapse, uncovered TCR pairs bring the potential for downstream off the shelf engineered T-cell therapeutics.
PUBLICATION
T-cell mediated cancer immunity
PUBLICATION
Tracking immune response to T-cell therapy
POSTER
Epitope-specific cytotoxicity achieved in TCR modified T-cells with reverse genetic engineering
PUBLICATION
Effector T-cells associated with improved survival
NEWS
iPair demonstrates efficacy of T-cell activating drug
Immune cell-based gene therapy for improved clinical outcomes
iRepertoire’s inclusive RepSeq+ chemistry provides a reproducible, quantitative measurement of donor T cell sequences with the potential of also tracking the CAR-T product in the context of a patient’s repertoire. After genetically engineering T-cells, immune profiling can also be used to ensure the diversity of the population of the final product. This recent case study reviews how iRepertoire’s single-cell iPair service was used to track TCR expansion and diversity.
CASE STUDY
Predicting patient response with TCR sequencing
PUBLICATION
Promoting CAR-T persistence and trafficking
Using single-cell sequencing to identify paired neo-epitope-specific TCRs during cancer vaccine development
Activated T cells responding to cancer neoantigens are extremely valuable to identify and sequence for subsequent therapeutic development but are difficult to detect from clinical specimens.
iRepertoire’s array of sensitive multiplex amplification chemistries provide the necessary tools for this critical first step in cancer vaccine development. For example, iPair single cell V(D)J receptor pairing was utilized to identify neo-epitope specific TCRs (paired TCR alpha and beta) directly from primary tumor cells in the highlighted study by Ott et. al.
PUBLICATION
Clincal trial of personalized neoantigen therapy
PUBLICATION
Vaccine development to confer antitumor immunity
PUBLICATION
Predicting melanoma patient response
WEBINAR
Predicting patient response to neoantigen vaccine and anti PD-1 therapy
NEWS
TCR repertoire as a biomarker for immunotherapy response
Reliable characterization of manufactured cell products like CAR-T cells and TILs
Scaling up manufacturing of cells can pose many risks. Does a process or cell reactor change or affect the cell product diversity or clonotype distribution? By utilizing immune repertoire profiling, changes to cell manufacturing can be assessed accurately and precisely. It is essential to characterize the uniformity of manufactured cell products to maximize efficacy and minimize adverse outcomes after transplantation. This poster provides data demonstrating static gaspermeable cell culture bags can be used for TIL cell therapy manufacturing.
POSTER
TIL cell therapy manufacturing with static gas-permeable cell culture bags
POSTER
Feasible TIL cell therapy manufacturing and treatment in patients with advanced NSCLC
Explore our services
Bulk immune repertoire profiling
Discover RepSeq+, our sensitive, quantitative, and high-throughput assay that combines multiplex PCR with NGS to analyze any combination of all seven chains of the adaptive immune system in a single reaction.
Single cell V(D)J profiling
Explore iPair, the first commercialized technology for capturing physically paired full-length V(D)J sequences in TCRs or BCRs from FACS isolated single cells in the same reaction well.
Data Analysis
Leverage our built-for-purpose, advanced AIRR analysis tools that translate raw sequence data into actionable insights.
Additional resources
Ready to get started?
iRepertoire serves as a leader in the field of immune repertoire profiling. We invite you to consult with our team of scientists to discover how our services can accelerate your analysis of immune cell function and diversity.